Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)

Hong Kong · Delayed Price · Currency is HKD

12.88

-0.28 (-2.13%)

Jul 10, 2026, 4:08 PM HKT

Market Cap	6.67B
Revenue (ttm)	57.61M +72.0%
Net Income	-273.20M
EPS	-0.59
Shares Out	517.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	864,899
Open	13.24
Previous Close	13.16
Day's Range	12.82 - 13.97
52-Week Range	12.61 - 96.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 26, 2026

About Xuanzhu Biopharmaceutical

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bisp... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2008

Employees 342

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2575

Full Company Profile

Financial Performance

In 2025, Xuanzhu Biopharmaceutical's revenue was 51.77 million, an increase of 72.03% compared to the previous year's 30.09 million. Losses were -245.51 million, -55.88% less than in 2024.

Financial numbers in CNY Financial Statements